Disc Medicine, Inc. $IRON Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund grew its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 168.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,852 shares of the company’s stock after purchasing an additional 10,576 shares during the quarter. New York State Common Retirement Fund’s holdings in Disc Medicine were worth $892,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock worth $71,000 after buying an additional 181 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Disc Medicine by 8.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after acquiring an additional 206 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Disc Medicine by 12.3% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,490 shares of the company’s stock worth $291,000 after acquiring an additional 600 shares during the period. CWM LLC boosted its position in shares of Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after acquiring an additional 711 shares during the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in Disc Medicine by 24.3% in the second quarter. KLP Kapitalforvaltning AS now owns 4,600 shares of the company’s stock valued at $244,000 after purchasing an additional 900 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on IRON. Morgan Stanley increased their price target on shares of Disc Medicine from $90.00 to $115.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, October 8th. National Bankshares set a $153.00 target price on Disc Medicine in a research report on Friday, October 17th. Truist Financial boosted their price target on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, Cantor Fitzgerald raised their price objective on Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Disc Medicine Stock Up 1.2%

Shares of Disc Medicine stock opened at $92.85 on Thursday. The company has a fifty day moving average price of $85.03 and a 200 day moving average price of $66.79. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $99.50. The stock has a market cap of $3.51 billion, a price-to-earnings ratio of -17.36 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.29). Equities research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 30,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $84.70, for a total value of $2,541,000.00. Following the completion of the sale, the chief operating officer owned 40,555 shares of the company’s stock, valued at $3,435,008.50. This trade represents a 42.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin Bitterman sold 70,000 shares of Disc Medicine stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $88.91, for a total transaction of $6,223,700.00. Following the sale, the director owned 385,549 shares in the company, valued at $34,279,161.59. This represents a 15.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 213,585 shares of company stock valued at $16,898,513. Insiders own 3.64% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.